Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-1140, CAPOX, and Keytruda in Biliary Tract Carcinoma
NCT05849480Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2024
- Primary completion
- Jun 2040
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CDX-1140 in biliary tract carcinoma (BTC), sponsored by National Cancer Institute. Started May 2024; status: recruiting.
02
Drugs
CDX-1140
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT05849480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849480.